Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.68 |
| ▸ | EGFR | P00533 | 8/20 | 0.59 |
| ▸ | ITK | Q08881 | 3/20 | 0.59 |
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | JAK1 | P23458 | 2/20 | 0.54 |
| ▸ | TYK2 | P29597 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 3/20 | 0.50 |
| ▸ | BLK | P51451 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21846824 | 1.00 | JAK3 (0.68) | JAK3EGFRITKJAK2JAK1 | |
| SCHEMBL21846822 | 0.93 | JAK3 (0.72) | JAK3EGFRITKJAK2JAK1 | |
| SCHEMBL21846879 | 0.90 | JAK3 (0.55) | JAK3EGFRITKJAK2BTK | |
| SCHEMBL29387364 | 0.90 | JAK3 (0.55) | JAK3EGFRITKJAK2BTK | |
| SCHEMBL21846873 | 0.90 | JAK3 (0.58) | JAK3EGFRITKJAK2JAK1 | |
| SCHEMBL29385619 | 0.90 | JAK3 (0.58) | JAK3EGFRITKJAK2JAK1 | |
| SCHEMBL14812608 | 0.86 | JAK3 (0.78) | JAK3EGFRJAK2JAK1TYK2 | |
| SCHEMBL21846825 | 0.86 | JAK3 (0.68) | JAK3EGFRJAK2JAK1TYK2 | |
| SCHEMBL29388306 | 0.86 | JAK3 (0.68) | JAK3EGFRJAK2JAK1TYK2 | |
| SCHEMBL21846862 | 0.85 | JAK3 (0.78) | JAK3EGFRJAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993603-B2 | Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and application thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE (CN) | 2024-05-28 | — | — | US | disclosed |
| US-20220048914-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048914-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | JAK1, JAK3, SSB | JAK3 2/4885EGFR 2648/4885ITK 255/4885 |
| US-11993603-B2 | Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and application thereof | JAK1, JAK3, SSB | JAK3 2/4885EGFR 2648/4885ITK 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.